TWO CASES OF SARS-COV-2 AND MYCOBACTERIUM TUBERCULOSIS CO-INFECTION: DIAGNOSIS AND TREATMENT

Lantharita Charoenpong1 , Kittisak Pholtawornkulchai2 , Nayot Panitantum1 and Patama Suttha1

Authors

  • Lantharita Charoenpong

Keywords:

co-infection, COVID-19, SARS-CoV-2, tuberculosis

Abstract

Co-infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and tuberculosis (TB) is infrequent. Here, we report two patients diagnosed with coronavirus disease 2019 (COVID-19) pneumonia together with pulmonary TB. Patient 1 is a 70-year-old male with COVID-19 pneumonia with acute respiratory distress syndrome (ARDS) complication and pulmonary TB who received darunavir plus ritonavir, chloroquine and favipiravir for COVID-19 ARDS, and standard anti-TB agents were adjusted to non-rifampicin (levofloxacin) regimen to avoid drug-drug interaction between protease inhibitors and rifampicin. Patient 2 is a 56-year-old male with COVID-19 pneumonia and miliary TB who received hydroxychloroquine, azithromycin and favipiravir for COVID-19 pneumonia, and a standard short course of rifampicin-based regimen for miliary TB. Given the prevalence of TB in Thailand, determination of TB co-infection among COVID-19 patients should lead to favorable clinical outcomes.

Published

2021-02-04